Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 440Diabetes Management and ResearchDiabetes Management and EducationDiabetes and associated disorders

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial

Open access

Abstract

Background The achievement of glycaemic control remains challenging for patients with type 1 diabetes. We assessed the effectiveness of day-and-night hybrid closed-loop insulin delivery compared with sensor-augmented pump therapy in people with suboptimally controlled type 1 diabetes aged 6 years and older. Methods In this open-label, multicentre, multinational, single-period, parallel randomised controlled trial, participants were recruited from diabetes outpatient clinics at four hospitals in the UK and two centres in the USA. We randomly assigned participants with type 1 diabetes aged 6 years and older treated with insulin pump and with suboptimal glycaemic control (glycated haemoglobin [HbA 1c ] 7·5–10·0%) to receive either hybrid closed-loop therapy or sensor-augmented pump therapy over 12 weeks of free living. Training on study insulin pump and continuous glucose monitoring took place over a 4-week run-in period. Eligible subjects were randomly assigned using central randomisation software. Allocation to the two study groups was unblinded, and randomisation was stratified within centre by low (<8·5%) or high (≥8·5%) HbA 1c . The primary endpoint was the proportion of time that glucose concentration was within the target range of 3·9–10·0 mmol/L at 12 weeks post randomisation. Analyses of primary outcome and safety measures were done in all randomised patients. The trial is registered with ClinicalTrials.gov, number NCT02523131, and is closed to accrual. Findings From May 12, 2016, to Nov 17, 2017, 114 individuals were screened, and 86 eligible patients were randomly assigned to receive hybrid closed-loop therapy (n=46) or sensor-augmented pump therapy (n=40; control group). The proportion of time that glucose concentration was within the target range was significantly higher in the closed-loop group (65%, SD 8) compared with the control group (54%, SD 9; mean difference in change 10·8 percentage points, 95% CI 8·2 to 13·5; p<0·0001). In the closed-loop group, HbA 1c was reduced from a screening value of 8·3% (SD 0·6) to 8·0% (SD 0·6) after the 4-week run-in, and to 7·4% (SD 0·6) after the 12-week intervention period. In the control group, the HbA 1c values were 8·2% (SD 0·5) at screening, 7·8% (SD 0·6) after run-in, and 7·7% (SD 0·5) after intervention; reductions in HbA 1c percentages were significantly greater in the closed-loop group compared with the control group (mean difference in change 0·36%, 95% CI 0·19 to 0·53; p<0·0001). The time spent with glucose concentrations below 3·9 mmol/L (mean difference in change −0·83 percentage points, −1·40 to −0·16; p=0·0013) and above 10·0 mmol/L (mean difference in change −10·3 percentage points, −13·2 to −7·5; p<0·0001) was shorter in the closed-loop group than the control group. The coefficient of variation of sensor-measured glucose was not different between interventions (mean difference in change −0·4%, 95% CI −1·4% to 0·7%; p=0·50). Similarly, total daily insulin dose was not different (mean difference in change 0·031 U/kg per day, 95% CI −0·005 to 0·067; p=0·09) and bodyweight did not differ (mean difference in change 0·68 kg, 95% CI −0·34 to 1·69; p=0·19). No severe hypoglycaemia occurred. One diabetic ketoacidosis occurred in the closed-loop group due to infusion set failure. Two participants in each study group had significant hyperglycaemia, and there were 13 other adverse events in the closed-loop group and three in the control group. Interpretation Hybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes. Funding JDRF, NIHR, and Wellcome Trust.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31947-0

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile *One patient had two severe hypoglycaemia events during run-in.
Figure 1 Trial profile *One patient had two severe hypoglycaemia events during run-in.CC BY · PubMed Central
Figure 2 Sensor glucose Median (IQR) concentrations in the closed-loop group (red line and shaded area; n=46) and the control group (blue line and shaded area; n=40) are shown. Dashed lines indicate the target glucose range (3·9–10·0 mmol/L).
Figure 2 Sensor glucose Median (IQR) concentrations in the closed-loop group (red line and shaded area; n=46) and the control group (blue line and shaded area; n=40) are shown. Dashed lines indicate the target glucose range (3·9–10·0 mmol/L).CC BY · PubMed Central
Figure 3 Cumulative distribution of percentage of time that sensor glucose was within the target range (ie, 3·9–10·0 mmol/L) over 12-week intervention phase by treatment group
Figure 3 Cumulative distribution of percentage of time that sensor glucose was within the target range (ie, 3·9–10·0 mmol/L) over 12-week intervention phase by treatment groupCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 440

Metadata

Authors
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., Beck, R. W., Acerini, C. L., Evans, M. L., Dunger, D. B., Elleri, D., Campbell, F., Bergenstal, R. M., Criego, A., Shah, V. N., Leelarathna, L., Hovorka, R., Alvarado, B., Ashanti, C., Baggott, J., Balakrishnan, K., Barber, N., Bath, L., Beasley, S., Beatson, C., Borgman, S., Bradshaw, S., Bugielski, B., Carlson, A., Collett, E., Curtis, J., Demmitt, J., Donahue, D., Exall, J., Forshaw, R., Hayes, J., Heath, S., Hellmann, A., Huegel, V, Hyatt, J., James, L., Joseph, H., Joshee, P., Konerza, W., Lum, J., Madden, M., Martens, T., McCarthy, C., McDonald, M., Mikityuk, V, Miles, H., Miller, D., Mubita, W., Murphy, C., Olson, B., Pad, R., Patibandla, N., Riding, K., Shaju, A., Thomas, L., Thomson, J., White, D., Yau, S., & Yong, J.
Affiliations
  • University of Cambridge (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Jaeb Center for Health Research (US)
  • Royal Hospital for Sick Children (GB)
  • Leeds Teaching Hospitals NHS Trust (GB)
  • University of Colorado Anschutz (US)
  • University of Manchester (GB)
Corresponding author
Hovorka, Roman
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-10
Volume
392
Issue
10155
Pages
1321-1329
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2890424595
Cited by
440
References
22
Citations by year
2026: 29 · 2025: 48 · 2024: 58 · 2023: 63 · 2022: 66 · 2021: 65 · 2020: 58 · 2019: 43 · 2018: 7
FWCI
34.39
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
Funders
  • University of Minnesota
  • Wellcome Trust (100574/Z/12/Z)
  • University Hospitals of Leicester NHS Trust
  • National Institute for Health and Care Research (100574/Z/12/Z)
  • NIHR Cambridge Biomedical Research Centre (100574/Z/12/Z)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
type 1 diabetes, hybrid closed-loop insulin delivery, sensor-augmented pump therapy, HbA1c, continuous glucose monitoring, insulin pump, time in target glucose range, glycemic control, children and adolescents, hypoglycemia
MeSH terms
Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Blood Glucose Self-Monitoring, Infusion Pumps, Implantable, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31947-0
The paper
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., Beck, R. W., Acerini, C. L., Evans, M. L., Dunger, D. B., Elleri, D., Campbell, F., Bergenstal, R. M., Criego, A., Shah, V. N., . . . Yong, J. (2018). Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31947-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.